LAUSR

Background. The SARS-CoV-2 pandemic changed the way the society functioned. The race to develop a rapid, non-invasive, widely available test resulted in multiple studies examining the potential of breath to be that ‘game changing test’. Breath sampling is a non-invasive point of care test, but SAR-CoV-2 has introduced a level of danger into collection and analysis that requires a change in workflow to keep staff and participants safe. We developed a SARS-CoV 2 breath test work flow for collection and processing of breath samples in an ambulatory care setting and prospectively evaluated the protocol. Protocol development included testing the effect of respiratory filters on the integrity and reproducibility of breath samples. Methods. Prospective, observational study conducted at community COVID-19 testing sites, collecting breath samples from patients presenting for RT-PCR testing. Breath was collected via Tedlar®, and/or BioVOC-2™ as well as an environmental sample for all participants. Samples were transferred to Tenex tubes, dry purged and analyzed using a Centri automated sample introduction machine, GC, and a Bench-ToF-HD. Results. We successfully collected and processed 528 breath samples from 393 participants at community-based ambulatory COVID-19 test sites. The majority of samples were collected before vaccines were available and throughout the emergence of the Delta Variant. No staff member was infected. Conclusion. We demonstrated a safe workflow for the collection, handling, transport, storage, and analysis of breath samples during the pandemic collecting highly infectious SARS-CoV-2 positive breath samples. This was done without filters as they added complexity to the breath matrix, jeopardizing the sample integrity.